NERV vs ALTO vs KO vs PEP vs ACAD

For growth investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus -4. 9% for Alto Ingredients, Inc. (ALTO). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 2x trailing P/E (54. 2x forward), making it the more compelling value choice. Analysts rate Minerva Neurosciences, Inc. (NERV) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 2x versus Alto Ingredients, Inc. at 35. 6x. On forward P/E, Alto Ingredients, Inc. is actually cheaper at 13. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: The Coca-Cola Company wins at 2. 26x versus PepsiCo, Inc. 's 5. 11x.

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

6%, compared to -81. 0% for Minerva Neurosciences, Inc. (NERV). Over 10 years, the gap is even starker: KO returned +121. 1% versus NERV's -94. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Minerva Neurosciences, Inc. 's 1. 28β — meaning NERV is approximately -738% more volatile than KO relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 2% for PepsiCo, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.

(ACAD) is pulling ahead at 11. 9% versus -4. 9% for Alto Ingredients, Inc. (ALTO). On earnings-per-share growth, the picture is similar: Alto Ingredients, Inc. grew EPS 119. 5% year-over-year, compared to -183. 5% for Minerva Neurosciences, Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus 0. 0% for Minerva Neurosciences, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus 0. 0% for NERV. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, The Coca-Cola Company (KO) is the more undervalued stock at a PEG of 2. 26x versus PepsiCo, Inc. 's 5. 11x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Alto Ingredients, Inc. (ALTO) trades at 13. 4x forward P/E versus 54. 2x for ACADIA Pharmaceuticals Inc. — 40. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALTO: 75. 4% to $10. 00.

In this comparison, PEP (3.

9% yield), KO (2. 5% yield), ALTO (0. 3% yield) pay a dividend. NERV, ACAD do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Both have compounded well over 10 years (KO: +121. 1%, NERV: -94. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NERV (Healthcare) and ALTO (Basic Materials) and KO (Consumer Defensive) and PEP (Consumer Defensive) and ACAD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NERV is a small-cap quality compounder stock; ALTO is a small-cap quality compounder stock; KO is a large-cap quality compounder stock; PEP is a mid-cap income-oriented stock; ACAD is a small-cap deep-value stock. KO, PEP pay a dividend while NERV, ALTO, ACAD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.